Avava lands $45M — a top-percentile beauty-tech raise — led by Catalio
What's the deal? Avava, a Boston medical aesthetics company, has raised $45 million in an early-stage round led by Catalio Capital ManagementDealroom has a profile for this one. Try Dealroom →. The financing splits into $30 million in equity and a $15 million debt facility, and includes new and existing investors.
What does Avava do? It builds energy-based aesthetics devices around its patented Focal Point Technology, which delivers energy to the skin while preserving surrounding tissue. The company says the approach enables customisable treatments across a range of skin types and body areas.
Why now? The raise follows Avava's recent launch of its AVAVA 2.0 software upgrade and lands as it advances clinical and regulatory programs. The company plans to use the capital to scale commercially, expand internationally, and fund its innovation pipeline.
Who's backing it? Catalio, a New York healthcare-focused investment firm, was Avava's first institutional investor and is leading both the equity and debt portions. UBS Investment BankDealroom has a profile for this one. Try Dealroom → and Oak Hill SecuritiesDealroom has a profile for this one. Try Dealroom → advised Avava on the deal.
What they said: "Catalio believed in our technology and our vision early, and their continued support speaks to the opportunity ahead of us," said chief executive officer Clint Carnell.
The signal: The round ranks in the top 1% of 106 early-stage wellness and beauty deals in the US over the past 48 months — an outsized bet on a sector where such large early rounds are rare. It signals investor appetite for hardware-driven aesthetics platforms with clinical ambitions.
Read more: benzinga.com
Image credit: Avava
